Cytosorbents Corp
NASDAQ:CTSO

Watchlist Manager
Cytosorbents Corp Logo
Cytosorbents Corp
NASDAQ:CTSO
Watchlist
Price: 0.6762 USD -0.72% Market Closed
Market Cap: 42.5m USD

Net Margin

-30.8%
Current
Improving
by 33.4%
vs 3-y average of -64.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-30.8%
=
Net Income
$-10.6m
/
Revenue
$34.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-30.8%
=
Net Income
$-10.6m
/
Revenue
$34.4m

Peer Comparison

Country Company Market Cap Net
Margin
US
Cytosorbents Corp
NASDAQ:CTSO
42.5m USD
Loading...
US
Abbott Laboratories
NYSE:ABT
188.9B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
188.5B USD
Loading...
US
Stryker Corp
NYSE:SYK
137.1B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
135.3B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
129.9B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
58.8B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
49.3B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
55.3B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
49B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.3B USD
Loading...

Market Distribution

Lower than 78% of companies in the United States of America
Percentile
22nd
Based on 15 072 companies
22nd percentile
-30.8%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Cytosorbents Corp
Glance View

Market Cap
42.5m USD
Industry
Health Care

CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Monmouth Junction, New Jersey and currently employs 221 full-time employees. The company went IPO on 2005-06-17. The firm is engaged in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via its polymer adsorption technology. The firm's lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy and pancreatitis. Its other products include animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. The firm's product candidates under development includes CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent and porous polymer beads.

CTSO Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-30.8%
=
Net Income
$-10.6m
/
Revenue
$34.4m
What is Cytosorbents Corp's current Net Margin?

The current Net Margin for Cytosorbents Corp is -30.8%, which is above its 3-year median of -64.2%.

How has Net Margin changed over time?

Over the last 3 years, Cytosorbents Corp’s Net Margin has increased from -114.6% to -30.8%. During this period, it reached a low of -114.6% on Sep 30, 2022 and a high of -28.4% on Jun 30, 2025.

Back to Top